Am J Psychiatry 2007 Sep;164(9):1437-8
|PDF Download - Full Text Link
( Please be advised that this article is hosted on an external website not affiliated with PubFacts.com)
J Am Acad Child Adolesc Psychiatry 2007 Mar;46(3):306-7
J Clin Psychopharmacol 2013 Apr;33(2):269-70
Expert Rev Neurother 2005 May;5(3):297-307
Duke University Medical Center, Department of Psychiatry and Behavioral Sciences, Durham, NC 27710, USA.
Aripiprazole is a recently released antipsychotic medication which differs from other atypical antipsychotic agents by its partial agonist activity at postsynaptic D2 receptors. It is administered orally and is distinguished by a long elimination phase half-life relative to other antipsychotic medications. Randomized studies have demonstrated the efficacy of aripiprazole relative to placebo in the treatment of acute relapse of schizophrenia and schizoaffective disorder, maintenance treatment of schizophrenia, and treatment of acute bipolar mania. Read More